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AbstrACt
Introduction Insomnia is a major public health concern. 
While cognitive behaviour therapy for insomnia (CBT-I) is 
acknowledged as the best available intervention, there 
are unanswered questions about its wider dissemination, 
socioeconomic benefits and its impact on health resource 
utilisation. The aim of this randomised controlled trial (RCT) 
is to investigate the effectiveness of a fully automated 
online version of CBT-I compared with online patient 
education about sleep (PE). Outcome measures comprise 
changes in symptoms of insomnia, time off work due 
to sick leave as well as medication and health resource 
utilisation. Also, we will examine (i) putative mediators of 
the effects of CBT-I on insomnia severity and (ii) selected 
potential psycho-bio-social moderators of the effects of 
the interventions.
Methods and analysis A parallel-group RCT will be 
conducted in a target sample of about 1500 adults 
recruited across Norway. Participants will complete an 
online screening and consent process. Those who meet 
eligibility criteria will be randomised to receive direct 
access to fully automated online CBT-I or to an online PE 
programme. The primary outcome is change in insomnia 
severity immediately postintervention; secondary 
outcomes are change in daytime functioning and other 
sleep measures postintervention and at 6-month and 
24-month follow-up. Objective data from national 
registries will be obtained at two time points (1 year and 
2 years post-treatment), allowing a mirror image study 
of preintervention and postintervention rates of sick 
leave, and of medication and healthcare utilisation by 
condition.
Ethics and dissemination The study protocol was 
approved by the Regional Committee for Medical and 
Health Research Ethics in South East Norway (2015/134). 
Findings from the RCT will be disseminated in peer-
reviewed publications and conference presentations. 
Exploratory analyses of potential mediators and 
moderators will be reported separately. User-friendly 
outputs will be disseminated to patient advocacy and other 
relevant organisations.
trial registration number NCT02558647; Pre-results.
IntroduCtIon  
Insomnia is characterised by a persistent 
inability to fall asleep, waking up during the 
night or too early in the morning and subse-
quent impairment in daytime functioning. 
It is the most commonly reported sleep 
problem, affecting 10%–12% of the popula-
tion1 and its prevalence has increased over 
the last decade.2 Insomnia is now the second 
most frequent health complaint (after pain) 
and represents an independent risk factor 
for the development of a wide range of 
mental and somatic conditions and illnesses.3 
Furthermore, spontaneous improvement in 
strengths and limitations of this study
 ► A large-scale, population-based trial with broad in-
clusion and lenient exclusion criteria and an extend-
ed follow-up period which may yield findings that 
are generalisable to real-world settings.
 ► National registers will offer objective data on the 
short-term and medium-term impact of cogni-
tive behaviour therapy for insomnia on rates of 
sick leave, and medication and health resource 
utilisation.
 ► Adequate statistical power to detect small effects 
on insomnia severity associated with the interven-
tions, and to analyse secondary outcomes such as 
preintervention and postintervention changes in sick 
leave, etc, and to undertake exploratory analyses of 
mediators and moderators.
 ► Many participants are self-referred or recruited by 
convenience sampling, which may introduce some 
self-selection biases.
 ► Reliance on online and self-report assessments is 
likely to lead to higher levels of sample attrition and/
or incomplete and missing assessment data com-
pared with studies that use face-to-face contact 
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insomnia is uncommon.4 Taken together, this demon-
strates that chronic insomnia is a significant public health 
concern.
The daytime consequences of insomnia, such as 
fatigue, psychological distress, physical discomfort and 
lower work productivity5 imply that insomnia impairs the 
quality of life of the individual,6 and increases healthcare 
and medication utilisation.7 Insomnia is further associ-
ated with increased rates of short-term and long-term sick 
leave, as well as permanent work disability.8–12 Growing 
awareness of the broad range of health and occupa-
tional effects of chronic insomnia has led to recognition 
that treating insomnia could have benefits that extend 
beyond symptomatic remission to include societal and 
economic gains.13 This is highlighted in a recent review 
by the National Institutes of Health and the Sleep Research 
Society which argued that, to realise the return on invest-
ment in sleep and circadian science, we need to accel-
erate the dissemination and implementation of research 
findings into clinical practice.14 Furthermore, the report 
suggested that the highest priority in insomnia research 
is to identify costs and economic impacts of screening, 
diagnosing and treating insomnia across different systems 
(eg, healthcare, employment, etc).14
While there is a growing consensus that cognitive 
behaviour therapy for insomnia (CBT-I) should be the 
first-line treatment option for insomnia,15 16 patients are 
however rarely offered such interventions even when they 
specifically present for medical assistance.17 Furthermore, 
there are often long waiting times to commence CBT-I 
because of a shortage of trained therapists.13 18 Arguably, 
the biggest current challenge to the dissemination of 
insomnia treatment is not a lack of empirical evidence 
for CBT-I, but lack of access to the intervention. Recently, 
this barrier has been partially overcome by delivering 
interventions via the internet.19 An online adaptation 
of CBT-I that seems to be particularly promising in this 
respect is the Sleep Healthy Using The internet (SHUTi) 
program.20 In a recent treatment trial, individuals with 
insomnia were randomised to receive either SHUTi or 
an online control condition. The researchers reported 
that 83% of participants allocated to SHUTi completed 
the intervention and 73% of them were in remission 
from insomnia at the 6 months follow-up assessment.20 
The short-term efficacy of SHUTi has been replicated in 
larger randomised controlled trials (RCTs) in the USA, 
Australia, Denmark and Norway, and findings suggest 
that online CBT-I has similar efficacy to CBT-I delivered 
in-person by a therapist.21–24 The long-term effectiveness 
of SHUTi compared with a control intervention has been 
investigated in one study; this demonstrated that symp-
toms of depression, anxiety and insomnia decreased 
significantly more postintervention in the SHUTi group 
and remained significantly lower in the SHUTi group for 
>18 months compared with a control group.25 A signifi-
cant advantage of SHUTi or similar online CBT-I inter-
ventions is that, as the programs are fully automated, 
they can be delivered entirely online, hence there is no 
specific need for direct contact with a health professional, 
enabling timely, direct access to the intervention and 
widespread dissemination.
As online CBT-I is a relatively recent innovation, there 
are still important questions to address regarding its wider 
benefits. For example, little is known about the effects of 
the intervention in large-scale studies, and/or in self-re-
ferred or convenience samples recruited cross-nationally 
and in samples completing the programme without any 
clinician input or researcher support. Also, data are sparse 
on the durability of the effects of online CBT-I in the 
medium-to-longer-term (ie, beyond 12–18 months).19 In 
addition, there is limited knowledge regarding its impact 
on basic health resource utilisation (beyond medication 
use alone), such as frequency of outpatient appoint-
ments, etc; and no studies have considered the broader 
economic perspective (eg, postintervention effects on 
rates of sick leave, etc). Furthermore, few studies have 
explored the putative moderators of or the mechanisms 
through which CBT-I (delivered face-to-face or online) 
may work.26
Aims
This paper describes the protocol for a two-arm RCT that 
assesses the benefits of online CBT-I compared with an 
alternative, active control intervention (online patient 
education about sleep (PE)). First, we will examine any 
differential change in the severity of insomnia, imme-
diately after completing the interventions. Second, we 
will examine if there are differential changes in symp-
toms of physical and mental health (eg, psychological 
distress, fatigue and health-related quality of life) imme-
diately postintervention, and whether any improvements 
in insomnia or other symptoms are reported at further 
follow-ups (6 months and 24 months post-treatment). 
Third, we will use national registry data collected routinely 
in Norway to compare rates of time off work due to sick 
leave days for up to 2 years before and after participating 
in the RCT, as well as monitoring medication and health 
resource utilisation according to condition in the same 
time interval. Fourth, we will try to extend the knowledge 
base about online interventions by undertaking explor-
atory analyses to assess whether change in specific clinical 
variables (eg, sleep variability, psychological measures of 
beliefs about sleep) mediate the effects of the CBT-I inter-
vention. Lastly (subject to additional funding to collect 
saliva samples), we will examine a subset of psycho-bio-
social factors to try to identify potential treatment moder-
ators that might inform the stratification of individuals 
with insomnia into ‘treatment-relevant’ subgroups in the 
future.
MEthods And AnAlysIs
The protocol for the RCT follows the Standard Protocol 
Items for Randomised Trials (SPIRIT) statement guide-
lines27 and is registered with the Clinical Trials website ( 
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SPIRIT statement can be found in online supplementary 
files 1 and 2, and a completed WHO Trial Registration 
Data Set can be found in online supplementary file 3.
The flow chart for the timeline for recruitment, 
follow-up assessments and for undertaking primary and 
secondary analyses of the RCT is shown in figure 1.
research design
This is a parallel-group superiority RCT comparing 
internet-delivered CBT-I (a Norwegian language version 
of SHUTi) with online PE. Recruitment for the study 
commenced in February 2016 and it is anticipated it will 
be completed by August 2018.
The consent and screening processes, self-rating proce-
dures and interventions will be undertaken entirely 
online. Potential participants will be first granted access 
to an online website where they will receive information 
about the RCT and be asked to provide online written 
informed consent to take part in the screening. If the 
screening process indicates the individual is eligible to 
participate, they are asked to complete a separate online 
consent process agreeing to take part in the randomisa-
tion process and the RCT.
Participants and procedure
Recruitment
Participants will be recruited from a variety of settings, 
for example, convenience sampling from health settings 
(undertaken by providing information about the RCT to 
general practice clinics, mental health and psychiatric 
outpatient settings), as well as self-referral via general 
advertisements and news stories in printed, online and 
social media.
As the investigators do not influence the online recruit-
ment procedure, we cannot stop recruitment as soon as 
1500 participants have given consent to be randomised 
and been allocated to an intervention. However, we can 
request information on the total sample size at intervals 
Figure 1 Flow chart of timeline for a randomised controlled trial of online interventions for insomnia (see text for predicted 
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of about 3 months. Thus, we will cease recruitment when 
a minimum sample of 1500 individuals have been 
randomised and given direct access to the interventions 
(ie, 750 per arm of the RCT).
Eligibility
Individuals who are interested in participating will enter 
an online screening portal (https:// sovnmestring. 
no) where they will be asked to provide online written 
consent to complete a series of self-ratings to ensure that 
they meet study eligibility criteria. These are as follows:
Inclusion criteria: individuals aged ≥18 years who 
score ≥12 on the Insomnia Severity Index (ISI)28 (a score 
indicative of insomnia symptoms that significantly impact 
on individuals).
Exclusion criteria: individuals scoring >10 on the 
Epworth Sleepiness Scale29 (which is suggestive of exces-
sive daytime sleepiness), and/or answering that they 
usually or every day snore and stop breathing and have 
difficulties staying awake during the day (ie, they posi-
tively endorse preselected indicators of sleep apnoea); 
self-report of the presence of any medical conditions 
where a fully automated CBT-I may be contraindicated 
(eg, epilepsy, bipolar disorder, schizophrenia or psychotic 
disorders and recent heart surgery) and/or participating 
in shift work.
All individuals deemed eligible for the RCT are provided 
with an onscreen notification stating that the online treat-
ment is text-based and if they have a reading disability 
(eg, dyslexia), they may find elements of the programme 
difficult to follow at times. After the prompt, the individ-
uals are then asked to respond to a further question to 
indicate that they still want to be included.
All individuals who are eligible for inclusion are 
provided with onscreen information that the intervention 
will require changes in their patterns of behaviour and 
are advised that this will imply that they need to set aside 
sufficient time to participate in the full course of therapy 
(usually, the six sessions can be completed within 6 to 9 
weeks). The notification indicates that potential partic-
ipants have the option to delay commencement of the 
programme if they wish. After the prompt, individuals are 
then asked to indicate whether they wish to continue and 
to be included in the randomisation process immediately.
Individuals who provide online written consent to 
participate are also asked to consent to the researchers 
accessing information about their health service use, 
medication prescriptions and selected national insurance 
data (related to time off work due to sick leave) from the 
relevant National databases (described below).
randomisation
Eligible participants who have provided online written 
informed consent will be randomised to one of two online 
conditions in a 1:1 ratio. The randomization procedure is 
automated, and the research team do not have any access 
to the process and cannot influence it in any way. Partici-
pants are blinded to the group to which they are assigned.
Interventions
Online CBT-I
The online version is a fully automated, interactive and 
tailored web-based program that incorporates the primary 
tenets of face-to-face CBT-I, including sleep restriction, 
stimulus control, cognitive restructuring, sleep hygiene 
and relapse prevention.20 22–24 30 Development of SHUTi 
is grounded in the model for internet interventions,22 
and follows best practice recommendations from the field 
of instructional design.23 The intervention targets the 
distinct needs of users, sets measurable learning objec-
tives and performance requirements and assesses users’ 
achievement of the targeted outcomes.
The SHUTi program is presented in six ‘cores’, 
metered out over time, with a new ‘core’ available 7 days 
after completion of the previous one. Each core has 
been developed to reflect the topics in the traditional 
weekly face-to-face CBT-I sessions and follows a similar 
general structure, namely: 1) examination of core objec-
tives, 2) review and feedback on homework and sleep 
diary data from the previous week, 3) teaching of new 
intervention material, 4) summary of the main points of 
the core and 5) assignment of homework. The content 
of the intervention is enhanced through a variety of 
interactive features, including personalised goal-setting, 
graphical feedback based on self-reported symptoms, 
animations and illustrations to enrich comprehension, 
quizzes to test and enhance user knowledge, vignettes 
to promote identification with material and video-based 
expert explanations. Also, automated emails are sent 
to users to increase their engagement and encourage 
program adherence.
Online PE
The online PE program employed in this trial has been 
used as a comparator for SHUTi in other published 
RCTs.23 24 The PE website provides fixed information 
about insomnia symptoms; the impact, prevalence and 
causes of insomnia; when to seek input from a doctor and 
basic lifestyle, environmental and behavioural strategies 
that may help to improve sleep. The content of the sleep 
education programme is based on a review of recommen-
dations provided on insomnia-focused websites.24
Both the PE and the CBT-I programmes incorpo-
rate some principles of CBT and both offer options for 
self-monitoring via sleep diaries and ratings of insomnia 
severity, but only the CBT-I programme employs online 
tools for self-monitoring. The PE programme offers 
printable pdf-documents. In contrast to CBT-I, the PE 
programme (1) does not personalise or individually 
tailor treatment recommendations based on user input; 
(2) presents significantly less detailed content, and in a 
simple, fixed format, without any interactive elements 
and (3) provides access to the entire programme content 
all at once, meaning the user can examine all the mate-
rials and content immediately (rather than the content 
being delivered in a step-by-step manner, or for access to 
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Concomitant care
There will be no restrictions on seeking other kinds of 
care during treatment.
Assessments
Descriptions for all measures used in this study are 
provided below and the timing of the assessments is 
summarised in table 1.
The primary outcome is change in severity of insomnia 
symptoms measured using the ISI28 at baseline and 9 
weeks postrandomisation. Other measures relate to 
secondary outcomes or are being used in exploratory or 
subsidiary analyses.
Demographics
Information will be collected at baseline on sex, age, 
marital status, years of education, employment status 
and if the participant has children living at home. Items 
recording marital status, children living at home and 




Insomnia severity index (ISI)s28: the ISI is a well-established, 
brief self-report instrument measuring the patient's 
perception of his or her insomnia that has good psycho-
metric properties and is validated for online use.31 It 
contains seven questions that assess the patients’ symp-
toms and consequences of insomnia, and any associated 
distress on a 0–4 rating scale. The ISI is administered 
at baseline, postintervention and 6 and 24 months 
follow-ups.
Other sleep measures
Sleep diary32: individuals are asked to provide daily subjec-
tive estimates of their sleep the previous night (eg, 
bed-time, sleep onset latency, wake after sleep onset, etc). 
Individuals keep a record for at least 10 of 14 consecu-
tive days and recordings are repeated at baseline, postin-
tervention and 6 and 24 months follow-ups; the data will 
be used in the secondary outcome and the mediation 
analyses.
Bergen Insomnia Scale33: comprises six items that assesses 
symptoms of insomnia based on the insomnia criteria 
found in the Diagnostic and Statistical Manual of Mental 
Disorders-IV-TR (American Psychiatric Association).34 
The self-rating is repeated at each assessment.
Brief Horne-Östberg Morningness-Eveningness Question-
naire35 (MEQ): the MEQ is the most widely used measure 
of chronotype (so-called ‘morningness’ or ‘evening-
ness’),36 and gives an indication of the respondents 
preferred (as opposed to actual) rise-time and bed-time.37 
We rate the brief 5-item version of the scale at baseline, 6 
and 24 months.
Brief Dysfunctional Beliefs and Attitudes Scale (DBAS-
16)38: a self-report questionnaire designed to identify 
maladaptive sleep-related and insomnia-related cogni-
tions. Patients are given a list of 16 statements reflecting 
different beliefs and attitudes about sleep, and they are 
asked to indicate on a 10-point scale how much they agree 
with the statements. The rating is completed at each 
assessment point and data will be used in the outcome 
and mediation analyses.
resource use and work productivity
Self-report information on these parameters will be anal-
ysed in conjunction with objective data from Norwegian 
national registries.
a. Self-report ratings are based on those used in stud-
ies of SHUTi and will allow for selected comparisons 
between the findings of the current RCT and other 
published research. The present protocol extends the 
duration of the follow-up period for these assessments 
(see table 1 for the schedule for each measure). The 
ratings include the following: use of healthcare services 
(five items, eg, recording use of primary and second-
ary health services, etc); medication use (reason for use, 
dosage, timing, adherence); help seeking behaviour (a 
10-item questionnaire that records what help or treat-
ments were sought for a given time period); absence 
from work due to health problems (five items); influence 
of health problems on productivity (two items recording 
self-perceptions of any negative effects of health status 
on work or leisure activities).
b. National registry data: data from national registers can 
be linked to individuals via their social security num-
ber. We will make requests for access to national data 
on at least two occasions: at 12-month follow-up, we 
will request data covering the 12 months pretreatment 
and 12 months post-treatment; likewise, at 24-month 
follow-up, we will request data covering the 24 months 
pretreatment and 24 months post-treatment. This will 
allow a review of the entire time frame of the study, 
to link objective data to the 6-month self-report as-
sessments, and to undertake mirror image analyses 
of rates of sick leave and of medication and health re-
source utilisation. The data that will be requested are 
as follows:
Norwegian Patient Registry (NPR): this contains infor-
mation about all patients who are waiting for, or have 
received treatment, as outpatients in the specialist health 
service. The data retrieved from the NPR include diag-
noses (according to the 10th revision of the International 
Statistical Classification of Diseases criteria), name of 
healthcare provider, service use (eg, outpatient appoint-
ments) and hospital admission and discharge dates.
National Insurance Administration: this records all 
periods of sick leave >13 days, as well as information on 
all disability pension awards (self-report information will 
allow us to estimate shorter periods of sick leave).
Norwegian Prescription Database (NorPD)39: this is a 
national health register comprising information on all 
prescriptions dispensed at Norwegian pharmacies (since 
January 2004). The NorPD provides detailed information 
that will allow us to identify the medication, its class and 
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Table 1 Key measures and timing of assessment
Screening* and/or baseline Postintervention 6 months 12 months 24 months
Demographics
  Sex X
  Age X
  Marital status X X X
  Number of children living at home X X X
  Years of education X
  Employment status X X X X
Sleep
  Insomnia Severity Index X X X X
  Bergen Insomnia Scale X X X X
  Brief Morningness-Eveningness 
Questionnaire 
X X X
  Sleep diary X X X X
  Brief Dysfunctional Beliefs and 
Attitudes Scale 16
X X X X
Physical and mental health
  Hospital Anxiety and Depression 
Scale
X X X X
  Chalder Fatigue Questionnaire X X X X
  Short Form-12 X X X X
  Physical health X X X X
  Mental health X X X X
  Pain problems X X X X
  Changes in health status X X X
Resource use and work productivity
  Health service utilisation (self-report 
and Norwegian Patient Registry)
X X X X
  Prescribed medications (self-
report and Norwegian Prescription 
Database)
X X X X X
  Sick leave (self-report and National 
Insurance Administration)
X X X X
  Impact on work productivity X X X
  Help seeking behaviours X X X
Health-related parameters
  Body mass index X X X X
  Alcohol Use Disorders Identification 
Test- Consumption
X X X X
  Physical activity X X X X
Electronic media and internet use
  Internet use X
  Electronic media use X X X X
  Internet intervention evaluation X X
  Long-term use of strategies X
  Negative effects of treatment X
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used as a proxy for medication consumption), especially 
those used to improve sleep.
other health measures
Given the known associations between insomnia and 
mental and physical disorders, alcohol use, body mass 
index (BMI), etc, we will also record other key items 
that will be relevant to statistical analyses that incorpo-
rate covariates. As shown in table 1, the following are 
completed at each assessment.
Physical and mental health
The following self-ratings will be repeated at each assess-
ment and findings from the postintervention assessment 
will be reported in the first publication (alongside sleep 
outcomes).
Hospital Anxiety and Depression Scale (HADS)40: the HADS 
comprises 14 items pertaining to non-vegetative symp-
toms of anxiety and depression, which makes it a suitable 
measure of general psychological distress in populations 
likely to have physical comorbidities (eg, general practice 
and liaison psychiatry settings).41
Chalder Fatigue Questionnaire (CFQ)42: the CFQ 
comprises 11 items addressing physical and psychological 
fatigue, and two items addressing the duration and the 
intensity of fatigue complaints.
Short Form-12 (SF-12)43 44: this is an abbreviated version 
of the MOS 36-item short-form health survey (SF-36), and 
measures the individuals’ perceived physical and mental 
health status. The SF-12 is scored using the recommended 
MOS software program that creates two summary scores, 
mental health (MCS12) and physical health (PCS12). 
The scores are represented as T-scores that are linear 
transformations with a mean of 50 and a SD of 10 in the 
general US population.
Other health assessment: additional instruments 
assessing various health domains are adapted from 
the HUNT study (the Nord-Trøndelag Health Study)45 
and assess: pain (eg, location, duration, stiffness, etc); 
physical health (a 20-item checklist of common medical 
conditions and any impact on work or personal life); 
mental health (an 8-item checklist of common psychi-
atric conditions based on a template used for physical 
health).
Other health-related parameters
BMI: height will be recorded at baseline and weight will be 
recorded at baseline, postintervention, 6 and 24 months 
to allow estimation of BMI at these time points.
Alcohol use disorders identification test-consumption (AUDIT-
C)46: the AUDIT-C scale comprises three items and will 
be used to assess the frequency and quantity of alcohol 
consumption at all assessment points.
Physical activity: will be measured using six items (from 
the HUNT study) that assess frequency, intensity and 
duration of the activity.
Additional measures related to exploratory analyses or 
subsidiary projects
Engagement with and acceptability of interventions
The acceptability of online interventions after comple-
tion of the programmes. The latter will be assessed using 
the internet intervention evaluation,30 which comprises two 
questionnaires used in SHUTi research: the Internet Inter-
vention Utility Questionnaire and the Internet Intervention 
Impact Questionnaire.
Self-report ratings will record participants’ familiarity 
with use of the internet at baseline and their electronic 
media use47 (five items) over time. These ratings will be 
used in subsidiary analyses as for example, baseline skills 
in using the internet may affect engagement with internet 
interventions and whether electronic media use changes 
post-treatment.
Views of internet treatment
To assess views regarding the interventions, we will ask 
participants to complete the Negative Effects Question-
naire (NEQ).48 The NEQ is a self-report measure that 
contains 32 items that are scored on a five-point Likert-
scale (0–4) and differentiates between negative effects 
that are attributed to psychological therapies and those 
possibly caused by other circumstances, as well as one 
open-ended question.
Use of sleep strategies questionnaire
A self-report questionnaire was developed in order to 
assess patients continued use of sleep strategies after 
the intervention. The questionnaire comprises six items 
assessing how much patients have used six different thera-
peutic techniques (kept a stable rise time, refrained from 
sleeping during daytime, used the bed and the bedroom 
only for sleeping, practised sleep restriction, got out of 
the bed when unable to fall asleep within 15–20 min and 
kept a sleep diary) and how useful each technique was. 
This will be administered at 24 months follow-up.
Potential moderators and mediators
We aim to undertake exploratory analyses of potential 
moderators (a moderator variable is one that influences 
the strength of a relationship between two other vari-
ables) and mediators (a mediator variable is one that 
explains the relationship between the two other vari-
ables) of the effects of CBT-I.49 For example, some of 
the data collected on demographics, physical health and 
mental health can be used to examine psycho-bio-social 
factors that may moderate the impact of CBT-I. However, 
if feasible, we will also extend the exploratory analysis of 
moderators to include ‘therapy-genetics’.
While pharmacogenetic studies are increasingly being 
undertaken in psychiatry, exploration of ‘therapy-ge-
netics’ is a relatively novel area of research,50 which aims 
to investigate the impact of specific genetic variants on 
differences in therapy outcome.51 Heritability estimates 
for insomnia range from 30% to 45%52 53 suggesting that 
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in the vulnerability to develop insomnia. We are seeking 
additional funding and ethical approval to undertake a 
subsidiary study to obtain (by post) a single salivary sample 
at 24 months from participants who provide specific 
written informed consent. If this subsidiary project will be 
implemented, we would aim to examine whether selected 
genotypes (which we demonstrated to be associated 
with insomnia in the HUNT study) are associated with 
larger improvements in insomnia symptoms following 
CBT-I (boosting effect) compared with other genotypes 
(including several single nucleotide polymorphisms).
As noted in the descriptions of measures, exploratory 
analyses of mediators of CBT-I will focus on data from the 
sleep diaries32 and the DBAS-16.38
sample size
The primary outcome is the difference in the change 
in ISI score from preintervention to postintervention 
according to group using an intent-to-treat (ITT) anal-
ysis. Findings from previous publications22 24 indicate 
large effect size (ES) differences even for comparisons 
between CBT-I and active control interventions such as 
PE (Cohen’s d>0.8). As such, we estimated that a sample 
size of approximately 486 participants would be sufficient 
to detect a moderate-to-large ES for the difference in the 
ISI score, at p<0.05 and with 80% statistical power. Impor-
tantly, this estimate takes into account a predicted attri-
tion rate of 50%22 24 and allows for missing data (which is 
often higher in studies undertaken online and/or reliant 
on self-report assessments). Also, this sample size allows 
us to detect significant ES differences for all secondary 
analyses undertaken at each follow-up point, including 
smaller effects (d~0.3 to 0.5) for selected variables (eg, 
HADS score), etc.
The larger sample size (n=1500) was selected because 
our goal is to have sufficient statistical power (80%) 
to detect significant differences (p<0.05) in rates of 
sick leave and health resource use. Guidance is limited 
regarding sample size estimates for these additional anal-
yses but, for example, we noted in a previous study by our 
research team that about 12% of patients diagnosed with 
insomnia at a sleep clinic in Norway are on sick leave.54 If 
we assume a similar prevalence of sick leave in the current 
study and predict an overall reduction in the prevalence 
of sick leave of 50% in the CBT-I group (from n=90 to 
45) and of 30% in the PE group (from n=90 to 63) by 
24 months follow-up, then a sample size of 1500 will allow 
detection of a significant between-group difference (OR 
1.7; 95% CI 1.01. to 2.79). Furthermore, even though 
the data recorded in national registries are unlikely to be 
subject to loss over time, we have allowed for 10% missing 
data (which would reduce the estimate OR 1.5), for 
example, due to failure to provide or accurately record 
social security number or difficulty in tracking personal 
information.
Given the exploratory nature of the moderator and 
mediator analyses and the lack of similar relevant studies 
in the literature, we did not undertake a sample size or 
statistical power calculation for these analyses. However, 
we note that the current sample exceeds the size of other 
completed or proposed mediator and moderator analyses 
of therapies.
data analysis plan
Outcome data will be released for analysis on three occa-
sions: after the total sample has completed the postin-
tervention assessments, and again after the total sample 
has completed the 12-month and 24-month follow-ups, 
respectively.
We plan to use a linear mixed model analysis to 
examine the primary outcome of change in ISI score 
between baseline and postintervention assessment, and 
to analyse secondary outcomes of the preintervention 
to postintervention change in other sleep and health 
measures. A mixed-model analysis (without constraints 
on the covariance structure) uses maximum likelihood 
estimation and is robust in the face of the predicted loss 
of data. The first publication will focus on the ITT anal-
yses, but may be accompanied by selected per-protocol 
analyses (if these provide a more direct comparison of 
our findings with others reported in the literature) and 
with preliminary findings regarding the acceptability of 
internet interventions. The results from the mixed-model 
analyses (estimated means and their SEs) will be used to 
calculate within-group and between-group preinterven-
tion to postintervention ES (Cohen’s d with 95% CIs) 
according to published recommendations.55 56 The same 
approach will be used for the planned analyses of self-re-
port data obtained at 6-month and 24-month follow-ups.
The main analysis of data regarding sick leave will 
examine time off work as a categorical variable (preva-
lence of sick leave per group) with findings reported 
using Χ2 and Fischer’s exact tests and ORs. However, 
number of days off sick will be assessed as a continuous 
variable and comparisons will include a mirror image 
study using t-tests to compare total days off per annum 
in the 12 (and then 24) months time period before 
and after randomisation according to group. Similar 
univariate and multivariate approaches will be used to 
analyse objective data regarding other health resource 
utilisation such as number of outpatient contacts, or of 
different classes of medication prescribed per group. 
Lastly, if the available data on sick leave meets require-
ments for complex survival analyses (eg, Weibull propor-
tional hazards model), we will consider modelling time 
to return to work (from sick leave) and/or time before 
taking sick leave according to group allocation.
Mediator and moderator analyses are exploratory, but 
both will follow the basic principle outlined by Kraemer 
et al.57 For example, we will explore whether change in 
level of DBAS-16 or variability in sleep patterns are poten-
tial mediators of outcome for CBT-I. Likewise, we will 
examine whether demographics (eg, age, sex), or co-oc-
curring health conditions, are moderators of the effect 
of CBT-I. Other subsidiary analyses will be reported sepa-
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Ethics and dissemination
All participants are required to provide informed consent 
before allocation to the online intervention programmes. 
The recruitment and consent process explain that partic-
ipation is voluntary; individuals can withdraw from the 
study at any time point without any consequences (eg, 
regarding their care or treatment) and access to the 
intervention programmes is independent of completion 
of follow-up self-ratings. Self-report data are recorded 
in electronic files that are encrypted and password 
protected. No identifying information is stored along-
side the self-report data. Furthermore, only researchers 
directly involved in data analysis will be granted super-
vised access to de-identified participant data.
The RCT findings will be disseminated in peer-reviewed 
publications and conference presentations. We expect to 
publish the findings regarding between-group differences 
in insomnia severity and daytime functioning at postin-
tervention, followed by an analysis of outcomes from 
later follow-ups. Findings from the analyses of data on 
sick leave and resource use will be published separately. 
Preliminary findings on putative mediators and modera-
tors of online CBT-I will be submitted only after the main 
outcome papers are published. User-friendly summaries 
of the findings and implications will be produced and 
disseminated to relevant patient-advocacy and other 
organisations.
The genotyping will be undertaken following ethical 
approval and adequate funding for postal collection of 
saliva samples.
PAtIEnt And PublIC InvolvEMEnt
The ‘Regionalt brukerutvalg, Helse Midt-Norge’ 
(patient user group for Central Norway Health Trust) 
were consulted regarding the original study outline (as 
submitted for funding) and provided feedback on the 
aims of the trial, the study design (eg, the assessment 
package and online screening procedure) and provided 
their endorsement for the protocol described in this 
manuscript. The findings of the study will be dissemi-
nated via academics, and by patient advocacy and other 
relevant public and community groups.
dIsCussIon
A major advantage of the RCT is that it provides eligible 
participants with direct access to online interventions that 
they can undertake without requiring clinical input or 
support. Ease of access and online recruitment enable us 
to draw on a national population and to recruit a larger 
sample size than most previous studies. However, it is 
possible that the sample recruitment may be biased in 
ways that are difficult to measure, for example, the RCT 
participants may be biased towards those who are reluc-
tant to seek help from healthcare professionals, those 
with intractable problems or those with multiple physical 
and mental comorbidities. Alternatively, if the sample 
comprises those with lower levels of impairment, the 
study may be underpowered to assess changes in resource 
utilisation, such as sick leave.
If CBT-I is shown to be statistically significantly more 
effective in the short- term and medium-term compared 
with PE, this may encourage its wider dissemination and 
utilisation within healthcare settings. As a minimum, it 
might be offered to individuals on waiting lists for face-
to-face therapy or online CBT-I could be recommended 
alongside other interventions provided by healthcare 
professionals. These initiatives would all help to increase 
the total number of individuals who could receive effec-
tive care.
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